grant

Microcalcifications in Atherosclerotic Plaque

Organization CITY COLLEGE OF NEW YORKLocation NEW YORK, UNITED STATESPosted 5 Sept 2022Deadline 31 Jul 2026
NIHUS FederalResearch GrantFY20253-D3-Dimensional3DAPOEAgreementAmericanApo-EApoE proteinApolipoprotein EApoptosisApoptosis PathwayAreaArterial Fatty StreakArteriesAtheromaAtheromatousAtheromatous degenerationAtheromatous plaqueAtherosclerotic capBiologicalBiological MarkersBiomechanicsBody TissuesBreast MicrocalcificationCalcifiedCardiac infarctionCardiovascularCardiovascular Body SystemCardiovascular Organ SystemCardiovascular systemCessation of lifeClinicalCollagenCoronaryCoronary VesselsDeathDescending aortaElementsEnvironmentFibrous CapFrequenciesGeometryHeart VascularHistologicHistologicallyHumanHypertensionImageInfiltrationInflammationIntrinsic factorKO miceKnock-out MiceKnockout MiceLeannessLeiomyocyteLesionLipidsLogistic RegressionsMMP InhibitorMMPsMacrophageMapsMatrix Metalloproteinase InhibitorMatrix MetalloproteinasesMechanical StressMechanicsMiceMice MammalsMicrocalcificationModelingModern ManMorphologyMurineMusMyocardial InfarctMyocardial InfarctionNecrosisNecroticNull MousePathologicPathological ConstrictionPatientsPlaque InstabilityPlaque RupturePlayProcessProgrammed Cell DeathPropertyRegression AnalysesRegression AnalysisRegression DiagnosticsResearchResolutionRiskRisk FactorsRisk ReductionRoentgen RaysRoleRuptureSamplingScanningSensitivity and SpecificityShapesSiteSmooth Muscle CellsSmooth Muscle MyocytesSmooth Muscle Tissue CellSpatial DistributionStatistical RegressionStenosisStressSudden DeathTestingThickThicknessThinnessThrombusTissue Inhibitor of MetalloproteinasesTissuesVascular Hypertensive DiseaseVascular Hypertensive DisorderVascular calcificationX-RadiationX-Ray RadiationX-rayXrayabsorptionacute coronary syndromeaged miceaged mouseaortic archatherosclerosis plaqueatherosclerotic lesionsatherosclerotic plaqueatherosclerotic plaque rupturebio-markersbiologicbiologic markerbiomarkerbiomechanicalcalcificationcardiac infarctcirculatory systemcontrast enhancedcoronary artery calcificationcoronary attackcoronary calcificationcoronary infarctcoronary infarctiondensitydigitalelderly miceexperienceheart attackheart infarctheart infarctionhigh blood pressurehigh riskhistologic imagehistological imagehuman tissuehyperpiesiahyperpiesishypertensive diseasehypertensive disorderimagingin vivomechanicmechanicalmechanical forcemeterold miceplaque capplaque vulnerabilityplaques in atherosclerosispreventpreventingreduce riskreduce risksreduce that riskreduce the riskreduce these risksreduces riskreduces the riskreducing riskreducing the riskresolutionsrisk-reducingsocial rolesoft tissuespecific biomarkersthree dimensionaltissue stressunstable plaquevasa vasorum
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

SUMMARY
Human fibroatheroma (FA) cap rupture leads to the formation of an occluding thrombus, myocardial infarction

(MI) and sudden death in more than half a million Americans every year. A vulnerable plaque is defined as a

positively remodeled lesion, rich in vasa-vasorum, characterized by smooth muscle cell apoptosis, and

containing a lipid rich pool with a fibrous cap that is infiltrated by macrophages. The current paradigm is that a

cap thickness < 65 µm (thin-cap FA or TCFA) is the key determinant of plaque vulnerability, and rupture occurs

when the cap tissue experiences a peak stress greater than 300 kPa. However, there are several other factors

that play an important role in the FA cap rupture, including atheroma morphology, biological environment, tissue

composition and mechanical forces. Indeed, whether the cap thickness is the single most important criterion

predicting plaque vulnerability is unclear, and the underlying mechanisms for atheroma cap rupture are still

insufficiently understood.

Vascular calcification has emerged among the factors that play an important role in the stability of plaque rupture.

For many decades, cardiovascular calcification has been considered as a passive process, accompanying

atheroma progression, correlated with plaque burden, and apparently without a major role on plaque

vulnerability. Clinical and pathological analyses have previously focused on the total amount of calcification

(calcified area in a whole atheroma cross section), and whether more calcification means higher risk of plaque

rupture or not. However, this paradigm has been changing in the last decade or so. Recent research has focused

on the presence of microcalcifications (µCalcs) in the atheroma, and more importantly on whether clusters of

µCalcs are located in the cap of the atheroma. While the vast majority of µCalcs are found in the lipid pool or

necrotic core, they are inconsequential to vulnerable plaque. We have also demonstrated to date the existence

of thousands of μCalcs primarily in non-ruptured human atheroma caps using µCT imaging, and that they behave

as an intensifier of the background circumferential stress in the cap. However, the similar X-ray absorption

properties of a thrombus and soft tissue complicates the analysis of μCalcs in ruptured FAs. To overcome this

limitation, we have developed a high-resolution contrast-enhanced µCT (CEµCT) approach to investigate

whether μCalcs co-localize with the site of FA cap rupture, in cases where an occluding thrombus is formed,

followed by myocardial infarction. The working hypothesis is that μCalcs in the FA cap has a major effect on the

FA cap rupture threshold. To test this hypothesis we propose to (1) determine the sensitivity and specificity of

μCalcs in the FA cap as a key biomarker of fibroatheroma rupture risk in human coronary vessels, and (2) to

characterize the increase in FA rupture risk due to μCalcs in the ApoE KO mice. If successful, the proposed

study will increase our understanding on vulnerable plaque rupture biomechanics and provide an alternative

paradigm for vulnerable plaque that will consider the effect of μCalcs in human atheroma cap rupture risk.

Grant Number: 5R16GM145474-04
NIH Institute/Center: NIH

Principal Investigator: Luis Cardoso

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →